Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-579 first-in-human monotherapy and combination study in advanced solid tumors
jRCT2080225298Phase 1Completed
- Sponsor
- Calico Life Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ABBV-CLS-579 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC) and 2 more (3 arms), sponsored by Calico Life Sciences. Started Jul 2020; status: completed.
02
Drugs
ABBV-CLS-579
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)microsatellite instability-high cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080225298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225298.